Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03122366 · ClinicalTrials.gov registry record
TLR4 Polymorphisms and Risk of Skin Cancer
A clinical trial, sponsored by University of Alabama at Birmingham.
- Completed
- Registry status
- 392
- Enrollment target
NCT03122366: Completed study, sponsored by University of Alabama at Birmingham.
NCT03122366 is a clinical trial that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 392 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03122366 has completed, sponsored by University of Alabama at Birmingham.
- COMPLETED
- Registry status
- 392 participants
- Enrollment target
Study Summary
Toll-like receptors (TLRs) play a key role in the innate immune system. Toll-like receptor-4 (TLR4) in particular, appears to play a role in susceptibility to cancer. Of 44 identified SNPs (small nucleotide polymorphisms) in TLR4, the most common is an A-G substitution at nucleotide position +896, downstream of the cDNA start codon, a missense mutation which leads to an amino acid substitution Asp299Gly in the third exon of the TLR4 gene. Pre-clinical studies from our laboratory have shown an association of TLR4 with ultraviolet radiation induced skin cancer. Hence, in this study we will assess the pattern of TLR4 polymorphisms and susceptibility to skin cancer.
Primary Outcome
TLR4 SNP Asp299Gly
Interventions
- DIAGNOSTIC_TEST Detection of single nucleotide polymorphisms (SNP)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 392 participants |
| Start Date | 2009-02-02 |
| Est. Completion | 2011-09-27 |
What the finished NCT03122366 record still lists
NCT03122366 is an observational study that tracks outcomes without assigning an intervention. The registered 392 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Detection of single nucleotide polymorphisms (SNP) is the first listed.
NCT03122366 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03122366 about?
NCT03122366 is a clinical study titled "TLR4 Polymorphisms and Risk of Skin Cancer". Toll-like receptors (TLRs) play a key role in the innate immune system. Toll-like receptor-4 (TLR4) in particular, appears to play a role in susceptibility to cancer. Of 44 identified SNPs (small nucleotide polymorphisms) in TLR4, the most common is an A-G substitution at nucleotide position +896, d...
What is the current status of trial NCT03122366?
This trial is currently completed. The enrollment target is 392 participants. The study started on 2009-02-02. Estimated completion is 2011-09-27.
What interventions are being tested in trial NCT03122366?
The interventions under investigation include: Detection of single nucleotide polymorphisms (SNP) (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03122366?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06397703 · 392 participants · Phase 2
ADT and SBRT vs SBRT Alone for Unfavorable Intermediate Risk Prostate Cancer
- NCT06625775 · 392 participants · Phase 1
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
- NCT07220967 · 392 participants · Phase 4
A Study of Antibiotic Delivery to Prevent Infection After Breast Tissue Expander Placement
- NCT07290036 · 392 participants · Phase 1
A Study to Learn if Bimekizumab Given in Different Ways is Safe and Moves Similarly Throughout the Body Over Time in Adults
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI